Guillain-barré syndrome

N Shahrizaila, HC Lehmann, S Kuwabara - The lancet, 2021 - thelancet.com
Guillain-Barré syndrome is the most common cause of acute flaccid paralysis worldwide.
Most patients present with an antecedent illness, most commonly upper respiratory tract …

Intensive care and treatment of severe Guillain–Barré syndrome

P Shang, J Feng, W Wu, HL Zhang - Frontiers in pharmacology, 2021 - frontiersin.org
Guillain–Barré syndrome (GBS) is an acute polyneuropathy mostly characterized by acute
flaccid paralysis with or without sensory/autonomous nerve dysfunction. Current immuno …

Novel immunological and therapeutic insights in Guillain-Barré syndrome and CIDP

L Querol, C Lleixà - Neurotherapeutics, 2021 - Springer
Inflammatory neuropathies are a heterogeneous group of rare diseases of the peripheral
nervous system that include acute and chronic diseases, such as Guillain-Barré syndrome …

Predicting outcome in Guillain-Barré syndrome: international validation of the modified Erasmus GBS outcome score

AY Doets, HF Lingsma, C Walgaard, B Islam, N Papri… - Neurology, 2022 - AAN Enterprises
Background and Objectives The clinical course and outcome of the Guillain-Barré syndrome
(GBS) are diverse and vary among regions. The modified Erasmus GBS Outcome Score …

Axonal variants of Guillain–Barré syndrome: an update

P Shang, M Zhu, Y Wang, X Zheng, X Wu, J Zhu… - Journal of …, 2021 - Springer
Abstract Axonal variants of Guillain–Barré syndrome (GBS) mainly include acute motor
axonal neuropathy, acute motor and sensory axonal neuropathy, and pharyngeal-cervical …

Guillain-Barré syndrome

KA Sheikh - CONTINUUM: Lifelong Learning in Neurology, 2020 - journals.lww.com
Guillain-Barré Syndrome : CONTINUUM: Lifelong Learning in Neurology Account Register
Activate Subscription Help Subscribe American Academy of Neurology Login Journal logo …

[HTML][HTML] Immunoglobulin and monoclonal antibody therapies in Guillain-Barré syndrome

YA Rajabally - Neurotherapeutics, 2022 - Elsevier
Guillain-Barré syndrome (GBS) is an acute autoimmune polyradiculoneuropathy affecting 1–
2 subjects per 100,000 every year worldwide. It causes, in its classic form, symmetric …

Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled …

C Walgaard, BC Jacobs, HF Lingsma… - The Lancet …, 2021 - thelancet.com
Background Treatment with one standard dose (2 g/kg) of intravenous immunoglobulin is
insufficient in a proportion of patients with severe Guillain-Barré syndrome. Worldwide …

Clinical presentation and symptomatology of Guillain-Barré syndrome: A literature review

C Elendu, EI Osamuyi, IA Afolayan, NC Opara… - Medicine, 2024 - journals.lww.com
Abstract Guillain-Barré Syndrome (GBS) is a rare but potentially life-threatening neurological
disorder characterized by acute onset ascending paralysis and sensory abnormalities. This …

Guillain–Barré syndrome

SE Leonhard, N Papri, L Querol, S Rinaldi… - Nature Reviews …, 2024 - nature.com
Guillain–Barré syndrome (GBS) is a rare immune-mediated polyradiculoneuropathy.
Patients typically develop rapidly progressive weakness and sensory deficits that can result …